You're reading the free version. Trader adds the live tape and alerts.
Start tracking
SYRE Conversion Disclosure
Fairmount Funds Management Llc · SEC Form 4 · Filed Jun 23, 2026
Conversion
Calculated transaction value
$0
Fairmount Funds Management Llc Director
SYRE
Spyre Therapeutics
SYRE
Transaction date
Jun 23, 2026
Public filing date
Jun 23, 2026
Filing lag
Filed same day
SYRE daily price context
Close on/before transaction
$97.05
Jun 23, 2026
First close after public filing
--
Unavailable
30-day return after filing
--
Through Unavailable
Source details
- Reported owner
- Not disclosed
- Source asset code
- Derivative
- Security
- Series B Preferred Stock on Common Stock
- Quantity / price
- 16,667 shares @ $0
- SEC ownership
- Indirect
- Transaction code
- C
- Form
- 4
- Filing identifier
- 0001104659-26-076967
Filing cohort
Transactions in this filing
Showing 3 of 3
Trades
3
Issuers
1
Estimated value
$399.66M
Buys / sales
0 / 1
| Issuer | Transaction | Traded | Value |
|---|---|---|---|
| Spyre Therapeutics, Inc. SYRE | Conversion | Jun 23, 2026 | Not reported |
| Spyre Therapeutics, Inc. SYRE | Sale | Jun 23, 2026 | $399.66M |
| Spyre Therapeutics, Inc. SYRE Current | Conversion | Jun 23, 2026 | $0 |